JP2021510725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021510725A5 JP2021510725A5 JP2020540394A JP2020540394A JP2021510725A5 JP 2021510725 A5 JP2021510725 A5 JP 2021510725A5 JP 2020540394 A JP2020540394 A JP 2020540394A JP 2020540394 A JP2020540394 A JP 2020540394A JP 2021510725 A5 JP2021510725 A5 JP 2021510725A5
- Authority
- JP
- Japan
- Prior art keywords
- osteosarcoma
- chondrosarcoma
- use according
- pharmaceutically acceptable
- anrotinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810058487.7A CN107970241B (zh) | 2018-01-22 | 2018-01-22 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
| CN201810058487.7 | 2018-01-22 | ||
| PCT/CN2019/071846 WO2019141170A1 (zh) | 2018-01-22 | 2019-01-16 | 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510725A JP2021510725A (ja) | 2021-04-30 |
| JP2021510725A5 true JP2021510725A5 (US20070167479A1-20070719-C00034.png) | 2021-06-17 |
| JP7324759B2 JP7324759B2 (ja) | 2023-08-10 |
Family
ID=62006233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540394A Active JP7324759B2 (ja) | 2018-01-22 | 2019-01-16 | 新規チロシンキナーゼ阻害剤であるアンロチニブの骨肉腫及び軟骨肉腫への使用 |
Country Status (6)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970241B (zh) * | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
| US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
| WO2020187152A1 (zh) * | 2019-03-15 | 2020-09-24 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
| CN111821459A (zh) * | 2019-04-17 | 2020-10-27 | 正大天晴药业集团股份有限公司 | 用于联合治疗骨肉瘤的喹啉类化合物 |
| CN111821302A (zh) * | 2019-04-18 | 2020-10-27 | 正大天晴药业集团股份有限公司 | 用于联合治疗软骨肉瘤的喹啉类化合物 |
| AU2020259565A1 (en) * | 2019-04-19 | 2021-12-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline compound or pharmaceutically acceptable salt thereof for treating Ewing's sarcoma |
| JP2022532189A (ja) * | 2019-05-10 | 2022-07-13 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 軟部肉腫の併用療法用キノリン誘導体 |
| EP3973963A4 (en) * | 2019-05-23 | 2023-06-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | QUINOLINE DERIVATIVES FOR THE TREATMENT OF HEAD AND NECK CANCER |
| CN114761010B (zh) * | 2019-11-25 | 2024-04-16 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物或其盐的联用药物组合物及其用途 |
| CN112043698B (zh) * | 2020-08-03 | 2023-04-25 | 吴宏伟 | 一组小分子药物在制备抑制肉瘤药物中的应用 |
| CN113456797B (zh) * | 2021-06-18 | 2024-03-08 | 暨南大学 | 长春碱类衍生物在制备治疗骨肉瘤和/或软组织肉瘤药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| US10709708B2 (en) * | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| CN107970241B (zh) * | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
-
2018
- 2018-01-22 CN CN201810058487.7A patent/CN107970241B/zh active Active
- 2018-09-20 WO PCT/CN2018/106625 patent/WO2019140937A1/zh active Application Filing
-
2019
- 2019-01-16 ES ES19740851T patent/ES2947685T3/es active Active
- 2019-01-16 JP JP2020540394A patent/JP7324759B2/ja active Active
- 2019-01-16 KR KR1020207024248A patent/KR20200111752A/ko not_active Application Discontinuation
- 2019-01-16 EP EP19740851.1A patent/EP3744325B1/en active Active
- 2019-01-16 CN CN201980008849.4A patent/CN111683661B/zh active Active
- 2019-01-16 WO PCT/CN2019/071846 patent/WO2019141170A1/zh active Application Filing
- 2019-01-16 CN CN202210965476.3A patent/CN115337304A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510725A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| JP2019536805A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2008530248A5 (US20070167479A1-20070719-C00034.png) | ||
| US9205098B2 (en) | Anti-cancer therapies | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2012180381A5 (US20070167479A1-20070719-C00034.png) | ||
| EP3445366A1 (en) | Method of treating liver cancer | |
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| RU2020124923A (ru) | Применение нового ингибитора тирозинкиназ, анлотиниба, при остеосаркоме и хондросаркоме | |
| RU2678103C2 (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
| JP2020520385A5 (US20070167479A1-20070719-C00034.png) | ||
| Sikic | BLEOMYCIN IN CERVICAL CARCINOMA: PROTOCOLS OF | |
| JP2006524678A (ja) | 耐性乳癌の治療のためのイリノテカンの使用 | |
| TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合 | |
| JP2020515649A5 (US20070167479A1-20070719-C00034.png) | ||
| KOBAYASHI | CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER INCORPORATING NEW CHEMOTHERAPEUTIC AGENTS | |
| JPWO2022216580A5 (US20070167479A1-20070719-C00034.png) | ||
| NZ740252B2 (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| JPWO2020243745A5 (US20070167479A1-20070719-C00034.png) |
